Stephens Inc. AR Has $395,000 Stock Holdings in Exelixis, Inc. $EXEL

Stephens Inc. AR cut its holdings in Exelixis, Inc. (NASDAQ:EXEL) by 87.8% in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 8,973 shares of the biotechnology company’s stock after selling 64,425 shares during the quarter. Stephens Inc. AR’s holdings in Exelixis were worth $395,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. GAMMA Investing LLC increased its position in Exelixis by 32.2% in the first quarter. GAMMA Investing LLC now owns 5,457 shares of the biotechnology company’s stock worth $201,000 after purchasing an additional 1,328 shares during the period. Cambridge Investment Research Advisors Inc. lifted its holdings in shares of Exelixis by 22.0% during the 1st quarter. Cambridge Investment Research Advisors Inc. now owns 84,092 shares of the biotechnology company’s stock valued at $3,105,000 after purchasing an additional 15,183 shares in the last quarter. Asset Management One Co. Ltd. bought a new position in shares of Exelixis during the 1st quarter valued at about $720,000. Spire Wealth Management lifted its stake in Exelixis by 15.3% in the 1st quarter. Spire Wealth Management now owns 10,391 shares of the biotechnology company’s stock valued at $384,000 after acquiring an additional 1,381 shares in the last quarter. Finally, Bartlett & CO. Wealth Management LLC bought a new stake in Exelixis in the 1st quarter valued at approximately $37,000. 85.27% of the stock is currently owned by institutional investors and hedge funds.

Exelixis Price Performance

Exelixis stock opened at $38.72 on Monday. The stock’s 50 day moving average is $38.68 and its 200 day moving average is $40.12. The firm has a market cap of $10.42 billion, a P/E ratio of 18.62, a P/E/G ratio of 0.78 and a beta of 0.38. Exelixis, Inc. has a one year low of $27.86 and a one year high of $49.62.

Exelixis (NASDAQ:EXEL) last posted its quarterly earnings data on Monday, July 28th. The biotechnology company reported $0.75 EPS for the quarter, topping analysts’ consensus estimates of $0.63 by $0.12. Exelixis had a return on equity of 27.47% and a net margin of 27.01%.The company had revenue of $568.26 million for the quarter, compared to analyst estimates of $574.36 million. During the same period in the previous year, the firm earned $0.84 earnings per share. The firm’s quarterly revenue was down 10.8% on a year-over-year basis. Equities analysts anticipate that Exelixis, Inc. will post 2.04 earnings per share for the current fiscal year.

Analysts Set New Price Targets

EXEL has been the topic of a number of analyst reports. The Goldman Sachs Group initiated coverage on Exelixis in a research note on Wednesday, September 17th. They set a “buy” rating and a $47.00 price objective on the stock. HC Wainwright decreased their price objective on shares of Exelixis from $53.00 to $46.00 and set a “buy” rating on the stock in a report on Tuesday, August 12th. Stifel Nicolaus upped their price objective on Exelixis from $38.00 to $41.00 and gave the company a “hold” rating in a report on Tuesday, July 29th. Leerink Partners raised Exelixis from a “market perform” rating to an “outperform” rating and set a $48.00 target price on the stock in a report on Tuesday, October 21st. Finally, Wall Street Zen raised Exelixis from a “hold” rating to a “buy” rating in a report on Friday, October 3rd. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating and ten have issued a Hold rating to the company. According to data from MarketBeat, Exelixis presently has an average rating of “Moderate Buy” and an average price target of $44.53.

About Exelixis

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.